Purpose: Following surgery for nonmetastatic renal cell carcinoma with tumor thrombus the risk of recurrence is significant but variable among patients. The purpose of this study was to develop and validate a predictive nomogram for individual estimation of recurrence risk following surgery for renal cell carcinoma with venous tumor thrombus. Materials and Methods: Comprehensive data were collected on patients with nonmetastatic renal cell carcinoma and thrombus treated at a total of 5 institutions from 2000 to 2013. Independent predictors of recurrent renal cell carcinoma from a competing risks analysis were developed into a nomogram. Predictive accuracy was compared between the development and validation cohorts, and between the nomogram and the UISS (UCLA Integrated Staging System, SSIGN (Stage, Size, Grade and Necrosis) and Sorbellini models. Results: A total of 636 patients were analyzed, including the development cohort of 465 and the validation cohort of 171. Independent predictors, including tumor diameter, body mass index, preoperative hemoglobin less than the lower limit of normal, thrombus level, perinephric fat invasion and nonclear cell histology, were developed into a nomogram. Estimated 5-year recurrence-free survival was 49% overall. Five-year recurrence-free survival in patients with 0, 1, 2 and more than 2 risk factors was 77%, 53%, 47% and 20%, respectively. Predictive accuracy was similar in the development and validation cohorts (AUC 0.726 and 0.724, respectively). Predictive accuracy of the thrombus nomogram was higher than that of the UISS (AUC 0.726 vs 0.595, p ¼ 0.001), SSIGN (AUC 0.713 vs 0.612, p ¼ 0.04) and Sorbellini models (AUC 0.709 vs 0.638, p ¼ 0.02).
FOLLOWING surgery for nonmetastatic RCC with tumor thrombus approximately 50% of patients have disease recurrence, making them ideal to study in adjuvant clinical trials. 1 Although the overall recurrence risk varies significantly, individual risk can be estimated using clinical and pathological variables. Since patients with nonmetastatic RCC with thrombus represent a relatively unique population, postoperative risk assessment may not be similar to that in other patients with RCC. In a prior study risk factors were identified and used to separate patients into favorable, intermediate and high risk groups with 79%, 55% and 22% 5-year recurrence-free survival, respectively, after surgery for RCC with thrombus. 2 However, to our knowledge a nomogram for individual risk assessment has not been previously described for this unique population of patients with RCC who are at high risk for recurrence after surgery.
Clinical trials of adjuvant therapy after surgery for RCC have been disappointing with the exception of the recent S-TRAC trial. 3 One persistent criticism of adjuvant clinical trial design is that there is significant heterogeneity of recurrence risk among enrolled patients. 4 Assigning accurate baseline risk is critical when trying to evaluate whether patients actually achieve a risk reduction from adjuvant therapies. In the recently published ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) and S-TRAC clinical trials patients were stratified into groups at intermediate and high risk for recurrence based on the well-known and validated UISS. 5 However, UISS and other systems 6, 7 were developed to stratify risk among a general population of patients with RCC. It is unclear how well this system performs to further stratify a population of patients at high risk such as those with nonmetastatic RCC with tumor thrombus.
Therefore, the purpose of our study was to develop a nomogram to predict individual 5-year recurrence risk after surgery in patients with nonmetastatic RCC with tumor thrombus, evaluate predictive accuracy in independent populations and compare the predictive ability of this nomogram with that of the UISS, SSIGN and Sorbellini 7 models. Preoperative assessment for metastatic disease was similar at each institution, including preoperative laboratory evaluation and computerized tomography or magnetic resonance imaging of the chest, abdomen and pelvis. All patients with radiographic or pathological evidence of distant metastatic or nodal metastases at presentation were excluded from analysis. No patients received systemic therapy preoperatively. Followup after surgery generally consisted of computerized tomography of the chest, abdomen and pelvis every 3 to 6 months for the first 5 years and yearly thereafter.
MATERIALS AND METHODS
The clinical and laboratory factors assessed in each patient were age, gender, BMI, tumor width and height, albumin levels, neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio, hemoglobin, creatinine and tumor diameter. The surgical and pathological factors assessed in each patient were year of surgery, grade, stage, thrombus level according to the system of Neves and Zincke, 8 sarcomatoid features, tumor histology, local and systemic symptoms, estimated blood loss, perinephric fat invasion and perioperative blood transfusion. All pathological specimens were examined by an institutional genitourinary pathologist. Histological subtypes were categorized according to the 2004 WHO classification.
To evaluate the effect of death from other causes we integrated competing risks analysis with univariate and multivariate Cox proportional hazard models to determine putative risk factors for RCC recurrence. 9 Significant variables following multivariate competing risks analysis were used to construct a predictive nomogram. The predictive accuracy of the nomogram was evaluated using ROC curves for the development and validation cohorts, and further evaluated for clinical applicability according to decision curve analysis. 10 Estimated RFS rates were calculated by the Kaplan-Meier method with p <0.05 considered statistically significant. SASÒ, version 9.4 or R, version 3.3.1 (https://www.r-project.org/) was used for all analyses.
RESULTS
A total of 636 patients with nonmetastatic RCC treated with radical nephrectomy and tumor thrombectomy were available for analysis. The supplementary table (http://jurology.com/) shows patient clinical and pathological characteristics. Median followup in the study period was 24.8 months (IQR 9.2e50.3). The tumor thrombus level was the renal vein in 342 cases (53.8%), level 1 in 92 (14.5%), level 2 in 100 (15.7%), level 3 in 45 (7.1%) and level 4 in 57 (9.0%).
Recurrent renal cell carcinoma was identified in 239 patients (37.5%) during followup. Competing risk analysis was done to identify variables associated with disease recurrence in the 465 patients in the development cohort (see table) . Independently predictive variables associated with recurrent RCC included tumor diameter in cm (HR 1.05, 95% CI 1.004e1.09, p ¼ 0.03), BMI (HR 0.97, 95% CI 0.95e0.997, p ¼ 0.03), preoperative hemoglobin less than the lower limit of normal (HR 1.59, 95% CI 1.11e2.27, p ¼ 0.01), thrombus level (HR 2.4, 95% CI 1.3e4.3, p ¼ 0.005), perinephric fat invasion (HR 1.5, 95% CI 1.05e2.02, p ¼ 0.03) and nonclear cell histology (HR 1.8, 95% CI 1.06e3.0, p ¼ 0.03).
Estimated 5-year RFS was 49% overall. When unweighted independent predictors were considered, 5-year RFS in patients with 0, 1, 2 and more than 2 risk factors was 77%, 53%, 47% and 20%, respectively (supplementary fig. 1 , http://jurology. com/).
Risk factors for recurrence were developed into a predictive nomogram for recurrent RCC after nephrectomy and tumor thrombectomy ( fig. 1) fig. 2 ). Decision curve analysis was performed to determine the potential clinical benefit of the nomogram to predict RCC recurrence at differing thresholds. Supplementary figure 2 (http://jurology.com/) shows decision curves of the net benefit. Decision curve analysis demonstrated the predictive ability of the nomogram for risk thresholds between 20% and 80%. Supplementary figure 3 (http://jurology.com/) shows recurrence sites.
Patients were classified according to the UISS system as previously described. 5 Kaplan-Meier estimated survival was determined according to UISS intermediate or high risk groups (p ¼ 0.001, fig. 3, a) . Using only patients in the UISS high risk cohort risk factors from the thrombus nomogram were able to further predict the recurrence risk with a 5-year RFS of 84%, 48%, 44% and 17% for 0, 1, 2 and more than 2 risk factors, respectively ( fig. 3, b) . Similarly in patients at intermediate UISS risk the number of risk factors using the thrombus nomogram was able to significantly predict recurrence risk with a 5-year RFS of 75%, 57%, 53% and 30% for 0, 1, 2 and more than 2 risk factors, respectively ( fig. 3, c) .
ROC curves were constructed to evaluate the predictive accuracy of the thrombus model vs the UISS, SSIGN and Sorbellini 7 models (fig. 4) . The predictive accuracy of the thrombus nomogram was 
DISCUSSION
Patients with nonmetastatic RCC with venous tumor thrombus are ideal candidates to study in adjuvant clinical trials because approximately 50% of them have nonmetastatic disease at presentation and approximately 50% experience recurrence following surgery. However, there is significant variability with respect to the individual recurrence risk. We present a predictive nomogram of the risk of 5-year recurrence, which was developed and validated in contemporary independent populations of patients treated at 5 centers.
Importantly the predictive accuracy of the nomogram was greater than that of the UISS model, which was used to stratify patients with RCC in recently reported, adjuvant therapy clinical trials. 3, 11 The low predictive accuracy of the original UISS model was not surprising as it included only 13.9% patients at high risk. 5 Similarly the SSIGN and Sorbellini 7 models were developed in general patients with RCC. These models have low predictive accuracy compared to the nomogram. Importantly the thrombus nomogram also demonstrated the ability to further stratify patients who were already identified as at high risk by the UISS model. Improved ability to identify individual recurrence risk in patients with nonmetastatic RCC with thrombus may allow for better postoperative patient counseling. It also facilitates ideal patient selection and analysis for future adjuvant therapy clinical trials.
When developing risk assessment tools that will be applied widely, multicenter data have advantages because such data minimize potential institutional biases. Using contemporary data is also helpful to avoid the inaccuracies associated with comparing patients treated in different decades during which imaging techniques, pathological definitions and surveillance regimens evolved significantly. However, because RCC with thrombus is relatively rare, many prior studies were done in patients treated at a single center of excellence during several decades, included those with and without metastasis, and used survival end points to stratify individual risk. 15 Recurrence following surgery is a more stable and clinically useful end point since survival of metastatic RCC changed significantly in the last decade.
11,16
Months following nephrectomy Furthermore, risk in patients with nonmetastatic RCC should be evaluated separately from that in patients with metastatic RCC since metastatic disease itself is the critical determinant of survival in these patients.
In the current series data on consecutive patients with nonmetastatic disease who were treated surgically at 5 independent centers since 2000 were used to create a risk prediction model with similar predictive accuracy in the development and validation cohorts. The model outperformed the current risk models for general RCC. In 2016 the S-TRAC clinical trial showed improved disease-free survival in patients who received sunitinib vs placebo.
3 If future studies demonstrate improved survival, many patients with nonmetastatic RCC with thrombus would be excellent candidates to begin adjuvant therapy following surgery.
It is estimated that 10% of all RCC tumors will have thrombus extension into the venous system. 17, 18 These patients are ideal for clinical trials of adjuvant therapy because they are at high risk for recurrence. Improving the ability to identify patients with RCC who are at highest risk will facilitate better clinical trial design and more accurate analysis when investigating future adjuvant therapies.
Decreasing heterogeneity in the trial population while targeting the patients at highest risk may also allow for easier identification of potential benefits using fewer patients. To date adjuvant clinical trials have used risk stratification tools that were developed for the general RCC population. In that population it is more appropriate to separate and exclude patients at low risk since 86% of these models were developed in those at low and intermediate risk. 5 Thus, they reflect the risk in a balanced population of patients with RCC overall. 19 However, since adjuvant clinical trials primarily seek to enroll patients at high risk, it is critical to use predictive models developed in high risk cohorts which enable stratification among a primarily high risk population. Patients with nonmetastatic RCC with thrombus are at high but variable risk for recurrence. They may benefit from improved baseline risk assessment when considering enrollment in future adjuvant therapy clinical trials. Limitations to this study include the retrospective approach and the subsequent potential for bias. There were likely subtle differences in diagnostic and treatment approaches at different centers which could have biased results. However, this multi-institutional approach may also enable findings to be more applicable at other centers.
To evaluate associations with recurrence risk and putative risk factors while adjusting for risk in patients who died of another cause postoperatively, we used competing risks analysis. The independent predictors in this study are similar to those in a prior study which did not use a competing risk model and also included tumor grade as a risk factor. 2 Tumor grade was not included in the final nomogram since there was no increase in predictive accuracy when grade was considered (AUC 0.724 vs 0.726, data not shown).
Data from 3 independent centers were included in the development cohort and data from 2 additional centers were used for validation. The variables that were evaluated in this study are commonly measured and should be able to be applied widely to measure risk. Also, common pathology traits were reviewed but there was no centralized pathology review. However, this approach more closely represents current practice.
Finally, the predictive accuracy of the nomogram measured by ROC curves was fair, similar in the development and test cohorts, and superior to the predictive accuracy of the UISS, SSIGN and Sorbellini 7 models.
CONCLUSIONS
Using multi-institutional contemporary data we developed a predictive nomogram with external validation for the 5-year recurrence risk following surgery for nonmetastatic RCC with thrombus. Improving risk assessment after surgery allows for improved postoperative counseling, and better design and analysis of future adjuvant clinical trials in patients at high risk who have RCC.
